Latest news for PVA TePla (OTC:TPLKF) Stock

PVA TePla AG is a Germany-based company that provides vacuum solutions for high-temperature and plasma treatment processes, as well as plant engineering solutions. The company operates through two segments: Industrial Systems and Semiconductor Systems. The Industrials Systems segment specializes in the development, construction, and marketing of vacuum heat treatment furnaces for processing materials at high temperatures. The Semiconductor Systems segment generates large revenue and provides systems for the semiconductor and solar industry ranging from systems for the production of silicon crystals for the semiconductor, solar, and optoelectronic industry to systems for plasma treatment in the semiconductor assembly. Its revenue is derived from the Asian market.

PVA TePla AG

PVA TePla

&nbsp;

<h2>Upgrades</h2>

<ul>
	<li>For Investors Bancorp Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISBC#NASDAQ">ISBC</a>), Stephens &amp; Co. upgraded the previous rating of Equal-Weight to Overweight. In the second quarter, Investors Bancorp showed an EPS of $0.34, compared to $0.18 from the year-ago quarter. The stock has a 52-week-high of $15.71 and a 52-week-low of $6.74. At the end of the last trading period, Investors Bancorp closed at $13.44.</li>
	<li>Loop Capital upgraded the previous rating for Leslies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) from Hold to Buy. Leslies earned $0.64 in the third quarter, compared to $0.47 in the year-ago quarter. The stock has a 52-week-high of $32.84 and a 52-week-low of $19.15. At the end of the last trading period, Leslies closed at $21.60.</li>
	<li>According to JP Morgan, the prior rating for Macy&#39;s Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) was changed from Underweight to Neutral. In the second quarter, Macy&#39;s showed an EPS of $1.29, compared to $0.81 from the year-ago quarter. The current stock performance of Macy&#39;s shows a 52-week-high of $22.30 and a 52-week-low of $5.57. Moreover, at the end of the last trading period, the closing price was at $21.61.</li>
	<li>According to HSBC, the prior rating for CF Industries Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) was changed from Hold to Buy. CF Industries Holdings earned $1.14 in the second quarter, compared to $0.89 in the year-ago quarter. The stock has a 52-week-high of $57.19 and a 52-week-low of $25.30. At the end of the last trading period, CF Industries Holdings closed at $43.34.</li>
	<li>For The Mosaic Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>), HSBC upgraded the previous rating of Hold to Buy. Mosaic earned $1.17 in the second quarter, compared to $0.11 in the year-ago quarter. The current stock performance of Mosaic shows a 52-week-high of $38.23 and a 52-week-low of $16.01. Moreover, at the end of the last trading period, the closing price was at $29.57.</li>
	<li>For FibroGen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>), Raymond James upgraded the previous rating of Underperform to Market Perform. FibroGen earned $1.45 in the second quarter, compared to $0.95 in the year-ago quarter. The stock has a 52-week-high of $57.21 and a 52-week-low of $11.47. At the end of the last trading period, FibroGen closed at $11.47.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>

&nbsp;

<h2>Downgrades</h2>

<ul>
	<li>For Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>), Cowen &amp; Co. downgraded the previous rating of Outperform to Market Perform. Phillips 66 earned $0.74 in the second quarter, compared to $0.74 in the year-ago quarter. At the moment, the stock has a 52-week-high of $94.34 and a 52-week-low of $43.27. Phillips 66 closed at $66.27 at the end of the last trading period.</li>
	<li>Argus Research downgraded the previous rating for Leidos Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) from Buy to Hold. For the second quarter, Leidos Holdings had an EPS of $1.52, compared to year-ago quarter EPS of $1.55. The current stock performance of Leidos Holdings shows a 52-week-high of $113.75 and a 52-week-low of $79.15. Moreover, at the end of the last trading period, the closing price was at $96.67.</li>
	<li>BTIG downgraded the previous rating for Performance Food Group Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>) from Buy to Neutral. In the fourth quarter, Performance Food Group showed an EPS of $0.56, compared to $0.86 from the year-ago quarter. At the moment, the stock has a 52-week-high of $59.89 and a 52-week-low of $31.69. Performance Food Group closed at $42.92 at the end of the last trading period.</li>
	<li>RBC Capital downgraded the previous rating for Duke Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) from Outperform to Sector Perform. In the second quarter, Duke Energy showed an EPS of $1.15, compared to $1.08 from the year-ago quarter. The current stock performance of Duke Energy shows a 52-week-high of $108.38 and a 52-week-low of $78.95. Moreover, at the end of the last trading period, the closing price was at $106.88.</li>
	<li>According to Raymond James, the prior rating for Healthcare Trust of America Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTA#NYSE">HTA</a>) was changed from Outperform to Market Perform. In the second quarter, Healthcare Trust showed an EPS of $0.44, compared to $0.42 from the year-ago quarter. The stock has a 52-week-high of $29.72 and a 52-week-low of $23.39. At the end of the last trading period, Healthcare Trust closed at $29.66.</li>
	<li>Raymond James downgraded the previous rating for Healthcare Realty Trust Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>) from Strong Buy to Market Perform. For the second quarter, Healthcare Realty Trust had an EPS of $0.43, compared to year-ago quarter EPS of $0.42. The stock has a 52-week-high of $34.01 and a 52-week-low of $26.77. At the end of the last trading period, Healthcare Realty Trust closed at $29.89.</li>
	<li>For Pinnacle West Capital Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>), Goldman Sachs downgraded the previous rating of Neutral to Sell. Pinnacle West Capital earned $1.91 in the second quarter, compared to $1.71 in the year-ago quarter. At the moment, the stock has a 52-week-high of $91.88 and a 52-week-low of $69.29. Pinnacle West Capital closed at $80.08 at the end of the last trading period.</li>
	<li>For Inovalon Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOV#NASDAQ">INOV</a>), BTIG downgraded the previous rating of Buy to Neutral. In the second quarter, Inovalon Holdings showed an EPS of $0.19, compared to $0.15 from the year-ago quarter. At the moment, the stock has a 52-week-high of $40.50 and a 52-week-low of $17.56. Inovalon Holdings closed at $40.32 at the end of the last trading period.</li>
	<li>Cowen &amp; Co. downgraded the previous rating for Ontrak Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) from Market Perform to Underperform. For the second quarter, Ontrak had an EPS of $0.12, compared to year-ago quarter EPS of $0.37. The stock has a 52-week-high of $99.89 and a 52-week-low of $11.51. At the end of the last trading period, Ontrak closed at $11.68.</li>
	<li>For Aprea Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>), JP Morgan downgraded the previous rating of Neutral to Underweight. In the second quarter, Aprea Therapeutics showed an EPS of $0.48, compared to $0.78 from the year-ago quarter. The current stock performance of Aprea Therapeutics shows a 52-week-high of $31.45 and a 52-week-low of $3.38. Moreover, at the end of the last trading period, the closing price was at $3.43.</li>
	<li>Goldman Sachs downgraded the previous rating for Intercept Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICPT#NASDAQ">ICPT</a>) from Neutral to Sell. For the second quarter, Intercept Pharmaceuticals had an EPS of $0.33, compared to year-ago quarter EPS of $1.92. The current stock performance of Intercept Pharmaceuticals shows a 52-week-high of $50.75 and a 52-week-low of $13.29. Moreover, at the end of the last trading period, the closing price was at $13.84.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>

&nbsp;

<h2>Initiations</h2>

<ul>
	<li>Oppenheimer initiated coverage on AngioDynamics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Perform rating. In the fourth quarter, AngioDynamics showed an EPS of $0.00, compared to $0.06 from the year-ago quarter. The current stock performance of AngioDynamics shows a 52-week-high of $30.25 and a 52-week-low of $8.95. Moreover, at the end of the last trading period, the closing price was at $27.36.</li>
	<li>Benchmark initiated coverage on Alterity Therapeutics Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) with a Speculative Buy rating. The price target for Alterity Therapeutics is set to $4.00. The stock has a 52-week-high of $3.58 and a 52-week-low of $1.09. At the end of the last trading period, Alterity Therapeutics closed at $1.28.</li>
	<li>With a Strong Buy rating, Raymond James initiated coverage on Byrna Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYRN#NASDAQ">BYRN</a>). The price target seems to have been set at $36.00 for Byrna Technologies. In the second quarter, Byrna Technologies earned $0.16. At the moment, the stock has a 52-week-high of $27.27 and a 52-week-low of $1.33. Byrna Technologies closed at $24.30 at the end of the last trading period.</li>
	<li>Piper Sandler initiated coverage on OppFi Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPFI#NYSE">OPFI</a>) with a Neutral rating. The price target for OppFi is set to $7.00.&nbsp;OppFi closed at $6.21 at the end of the last trading period.</li>
	<li>William Blair initiated coverage on Ryan Specialty Group Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAN#NYSE">RYAN</a>) with an Outperform rating. &nbsp;Ryan Specialty Group closed at $30.25 at the end of the last trading period.</li>
	<li>For WSFS Financial Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSFS#NASDAQ">WSFS</a>), Seaport Global initiated coverage, by setting the current rating at Neutral. WSFS Financial earned $2.00 in the second quarter, compared to $0.46 in the year-ago quarter. At the moment, the stock has a 52-week-high of $55.18 and a 52-week-low of $24.59. WSFS Financial closed at $44.24 at the end of the last trading period.</li>
	<li>HC Wainwright &amp; Co. initiated coverage on NextPlay Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTP#NASDAQ">NXTP</a>) with a Buy rating. The price target for NextPlay Technologies is set to $3.00. Interestingly, in the fourth quarter, NextPlay Technologies&#39;s EPS was $0.61. The stock has a 52-week-high of $2.39 and a 52-week-low of $1.62. At the end of the last trading period, NextPlay Technologies closed at $1.81.</li>
	<li>With a Buy rating, Goldman Sachs initiated coverage on Perella Weinberg Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWP#NASDAQ">PWP</a>). The price target seems to have been set at $16.50 for Perella Weinberg Partners. Interestingly, in the second quarter, Perella Weinberg Partners&#39;s EPS was $0.32. The stock has a 52-week-high of $14.60 and a 52-week-low of $11.84. At the end of the last trading period, Perella Weinberg Partners closed at $13.29.</li>
	<li>Keybanc initiated coverage on Janus International Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBI#NYSE">JBI</a>) with an Overweight rating. The price target for Janus Intl Gr is set to $18.00. In the second quarter, Janus Intl Gr showed an EPS of $0.02, compared to $0.17 from the year-ago quarter. The current stock performance of Janus Intl Gr shows a 52-week-high of $15.50 and a 52-week-low of $12.06. Moreover, at the end of the last trading period, the closing price was at $14.45.</li>
</ul>

<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Upgrades

Downgrades

Initiation

Intraday Update

Analyst Ratings

ANGO

APRE

ATHE

BPMP

BYRN

FGEN

ICPT

INOV

ISBC

LDOS

LESL

NXTP

OPFI

OTRK

PFGC

RYAN

SFBS

TPLKF

WSFS

Benzinga's Top Ratings Upgrades, Downgrades For August 20, 2021

Berenberg downgrades PVA TePla (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TPLKF#OTC">TPLKF</a>) from Buy to Hold.

News

Berenberg Downgrades PVA TePla to Hold

Comments

PVA TePla

News

Latest news for PVA TePla (OTC:TPLKF) Stock

Friday, August 20, 2021

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga